Pfizer Global Antimicrobial Surveillance Programs

Program Objectives

The goal of Pfizer supported surveillance programs is to monitor global changes in bacterial resistance patterns.

What are the health needs and challenges?

Understanding evolving bacterial resistance patterns is a key element in managing the rise of antimicrobial resistance (AMR). These data can be used to inform antimicrobial resistance mitigation strategies and provide physicians and healthcare practitioners with information to assist in the selection of appropriate treatments for their patients.

Description of partnership activities and how they address needs and challenges

  1. Pfizer’s Antimicrobial Testing Leadership and Surveillance (ATLAS) program (formerly TEST) has monitored changing bacterial resistance patterns for over 13 years across more than 60 countries.   It provides physicians and the healthcare community with cumulative data on bacterial surveillance.  Data from this effort have been reported in manuscripts and congress abstracts.    These cumulative data are also accessible through a publicly available web site ( that offers an interactive platform to enable physicians to evaluate data, conduct analyses, and export tables and figures corresponding to specific countries and regions, and customized by pathogen(s) and antibiotic(s). The ATLAS database is updated every 6 months with emerging data from over 200 institutions around the world.  ATLAS access is also available through a mobile App to enable data access at the point of care.

  2. The LEADER Program, established in 2004, is a national (US) initiative to monitor the activity of linezolid and comparator agents against target Gram-positive pathogens.

  3. The SENTRY Antimicrobial Surveillance Program, which began in 1997 and is managed by JMI Laboratories, was designed to monitor the predominant pathogens and antimicrobial resistance for both nosocomial and community-acquired infections globally.  Each year, the program surveys over 30,000 Gram-positive and Gram-negative organisms from medical centers participating in the global study.

  4. The TEST program was established in 2004 and is a global program that tracks antibiotic resistance for both Zyvox and Tygacil antibiotics as well as other antibiotics. The scope of the TEST program (2004-2016) has reached 2,700 sites in 69 countries (cumulative total) since inception. Currently, the program holds 200 active sites in 52 countries. Since 2004, the TEST program has provided valuable data and information – generating over 360 posters and 57 peer reviewed manuscripts to date. Results are available on a web-based interactive platform that includes a dynamic database of “real-time” surveillance data

  5. The Global Antifungal Surveillance Program determines the frequency of occurrence of resistance among fungal pathogens causing infections in hospitalized patients. This global program includes 62 participating medical centers in the SENTRY Program, located in North America, Latin America, Europe, and the Asia-Pacific region.

  6. China-based antibiotic resistance surveillance programs:  Since 2005, CHINET has investigated the anti-bacterial resistance and susceptibility rate of clinical isolates from major regions in China. It has accumulated around 600,000 isolates so far and will also expand its coverage to all regions in 2017.CHIFNET investigates the anti-fungal resistance and susceptibility rate from all the regions since 2009, with about 3,500 isolated collected per.

Corresponding principle in the declaration

“We are committed to antibiotics only being used in patients who need them, we support continued education for clinical professionals on appropriate use, and we welcome the WHO Global Action Plan’s focus on improved stewardship”. 

Read full Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance (AMR)

An important component of stewardship is the ability to identify and track antimicrobial resistance occurrence and trends.  This not only allows us to evaluate the effectiveness of stewardship programs, but it also enables public health officials to identify new emerging AMR problems.

Partnership information

Company(ies) Pfizer

Therapeutic Focus Infectious Diseases

Disease(s) Drug-Resistant Infections (AMR)

Program Type(s) Research & Development - Operations Research


Start Date 1997

More information GCP Susceptibility Data Sentry Antimicrobial Surveillance

Anticipated completion date Ongoing